Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2004;103:261-266
© 2004 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waetjen, L. E.
Right arrow Articles by Cummings, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waetjen, L. E.
Right arrow Articles by Cummings, S. R.
Related Collections
Right arrow General gynecology
Right arrow Geriatrics
Right arrow Urogynecology

ORIGINAL RESEARCH

Effect of Raloxifene on Urinary Incontinence: A Randomized Controlled Trial

L. Elaine Waetjen, MD, Jeanette S. Brown, MD, Katharina Modelska, MD, Terri Blackwell, MA, Eric Vittinghoff, PhD and Steven R. Cummings, MD for the MORE Study Group

From the Department of Obstetrics and Gynecology, University of California, Davis; Department of Epidemiology and Biostatistics, University of California, San Francisco; Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco; and San Francisco Coordinating Center, Research Institute at California Pacific Medical Center, San Francisco, California.

Address reprint requests to: L. Elaine Waetjen, MD, Assistant Professor, Department of Obstetrics and Gynecology, 4860 Y Street, Suite 2500, Sacramento, CA 95817; e-mail: lewaetjen{at}ucdavis.edu.

OBJECTIVE: To estimate the effect of 3 years of treatment with raloxifene on urinary incontinence in postmenopausal women.

METHODS: We used measures of urinary incontinence severity, frequency, and type in the Multiple Outcomes of Raloxifene trial, a multicenter randomized, controlled trial of women who were at least 2 years postmenopausal with osteoporosis. At 10 U.S. sites of this trial, 963 women randomly assigned to raloxifene or placebo completed questionnaires about incontinence at baseline and 3 years later. We analyzed the odds of worsening severity and frequency of incontinence and type of incontinence after 3 years of treatment with raloxifene.

RESULTS: The mean age of our subjects was 68.3 ± 7 years. After 3 years of treatment, there was no significant difference between raloxifene and placebo groups in urinary incontinence severity (multivariable odds ratio [OR] 1.02; 95% [CI] 0.78, 1.34). The majority of the women (60%) had no change in urinary incontinence episodes from baseline to year 3. The odds of worsening urinary incontinence severity after 3 years of raloxifene treatment were 1.05 (95% CI 0.75, 1.48). Similarly, the odds of developing new onset incontinence were 0.95 (95% CI 0.59, 1.52). Finally, raloxifene did not effect the odds of having stress (OR 1.01; 95% CI 0.71, 1.43) or urge (OR 1.20; 95% CI 0.86, 1.68) incontinence after 3 years of use.

CONCLUSION: In postmenopausal women with osteoporosis, 3 years of treatment with raloxifene had no effect on urinary incontinence.

LEVEL OF EVIDENCE: I




This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
T. A. Shamliyan, R. L. Kane, J. Wyman, and T. J. Wilt
Systematic Review: Randomized, Controlled Trials of Nonsurgical Treatments for Urinary Incontinence in Women
Ann Intern Med, March 18, 2008; 148(6): 459 - 473.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
U. Veronesi, P. Maisonneuve, N. Rotmensz, B. Bonanni, P. Boyle, G. Viale, A. Costa, V. Sacchini, R. Travaglini, G. D'Aiuto, et al.
Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy
J Natl Cancer Inst, May 2, 2007; 99(9): 727 - 737.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. R. Land, D. L. Wickerham, J. P. Costantino, M. W. Ritter, V. G. Vogel, M. Lee, E. R. Pajon, J. L. Wade III, S. Dakhil, J. B. Lockhart Jr, et al.
Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
JAMA, June 21, 2006; 295(23): 2742 - 2751.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
L. E. Waetjen, J. S. Brown, E. Vittinghoff, K. E. Ensrud, J. Pinkerton, R. Wallace, J. L. Macer, D. Grady, and for the Ultra Low Dose Transdermal estRogen Assess
The Effect of Ultralow-Dose Transdermal Estradiol on Urinary Incontinence in Postmenopausal Women
Obstet. Gynecol., November 1, 2005; 106(5): 946 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
L.M. Helvering, M.D. Adrian, A.G. Geiser, S.T. Estrem, T. Wei, S. Huang, P. Chen, E.R. Dow, J. N. Calley, J.A. Dodge, et al.
Differential Effects of Estrogen and Raloxifene on Messenger RNA and Matrix Metalloproteinase 2 Activity in the Rat Uterus
Biol Reprod, April 1, 2005; 72(4): 830 - 841.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
Genitourinary Tract Changes
Obstet. Gynecol., October 1, 2004; 104(4_suppl): 56S - 61S.
[Full Text] [PDF]

Home page
 Obstet GynecolHome page
J. L. Lowder and A. M. Weber
Effect of Raloxifene on Urinary Incontinence: a Randomized Controlled Trial
Obstet. Gynecol., July 1, 2004; 104(1): 197 - 198.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Obstetricians and Gynecologists.